INT-001 Validates Moderna's Oncology Platform, but the Market Reactions in MRNA and MRK Exceed the Current Fundamental Contribution

Overview

The report addresses the core investor questions arising after the positive INT-001 results, evaluating their clinical implications, the value of Moderna's platform, the serviceable market, Merck's economics, competitive implications, and the rationale behind the biopharmaceutical sector's rally. It concludes that the clinical and platform validation is materially significant, but the current market reaction also incorporates platform optionality, short covering, and headline effects and cannot be fully explained by the sales and profit opportunity of the existing INT programs.

Core views

First, INT-001 achieved positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results at the first interim analysis of its Phase III melanoma trial. Because interim analyses generally require crossing a high efficacy threshold, the report estimates that the RFS hazard ratio may be approximately 0.65 to 0.50 and that DMFS may be close to the Phase II reference level of 0.40. These are not formally disclosed company results, as the specific hazard ratios and statistical data remain under embargo. Beyond demonstrating INT's efficacy in melanoma, the more important implication is that this is the first pivotal trial to prove that Moderna's mRNA platform can be used outside respiratory vaccines and the company's first major success in a non-infectious disease. Moderna's investor relations team also described it as the first immuno-oncology regimen in this setting to outperform Keytruda monotherapy after multiple immuno-oncology combinations had failed. Second, the report believes the platform opportunity is considerable, but the existing clinical landscape and market size need to be defined accurately. INT has 4 Phase III studies, including melanoma and 3 non-small cell lung cancer studies, as well as 5 Phase II studies covering potentially registrational renal cell carcinoma, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, first-line metastatic non-small cell lung cancer, and melanoma. The epidemiological opportunity covered by INT-001 represents approximately 30% of the addressable population in the current pivotal programs and 17% of all Phase II and Phase III INT studies. Bernstein's non-risk-adjusted sales model for early-stage melanoma and lung cancer is US$2.4 billion. As a scale reference, revenue from Keytruda's early-stage cancer indications was approximately US$7.920 billion in 2025 and is projected to reach US$9.173 billion in 2028. The report summarizes this as approximately US$8 billion currently and a peak of approximately US$9 billion, noting that it remains below US$10 billion through 2028. The INT programs overlap only partially with Keytruda's early-stage indication portfolio, notably excluding triple-negative breast cancer, cervical cancer, and head and neck cancer, so Keytruda's entire early-stage market cannot be treated directly as the INT opportunity. However, INT is expected to be priced above Keytruda. Moderna previously discussed a price range between Keytruda and CAR-T therapy but did not narrow it further this time. Third, the report distinguishes clinical value from the share-price reaction. MRNA rose approximately 170% following the news, but the report believes that even including the entire existing portfolio of pivotal INT programs would be insufficient to explain the magnitude of the increase in market capitalization. The rally was jointly driven by three factors: the positive results prompted investors to reimagine applications of the mRNA platform beyond respiratory vaccines; approximately 15% of the float had previously been sold short, triggering short covering; and headlines about a successful “cancer vaccine” attracted retail investors who had previously shown limited participation. Moderna's investor relations team believes the mature and consistent Phase II results had already substantially reduced clinical risk, but once the remaining risk was removed, under-positioned investors increased exposure simultaneously, further amplifying the move. The report's August 20, 2026 data table shows MRNA at a closing price of US$174.38 and a target price of US$45.00, with relative performance of 528.3% in the table, while Bernstein continues to rate it Market-Perform. Fourth, INT should not be understood as a mass-market prophylactic vaccine. Intismeran autogene is used in patients who have or previously had cancer to clear minimal residual disease during adjuvant treatment after tumor resection, rather than to prevent cancer in healthy people. Its manufacturing process sequences each patient's resected tumor, uses an algorithm to select up to 34 patient-specific neoantigens, and then manufactures an individualized mRNA construct on demand to induce new neoantigen-specific T-cell clones. Although it uses the mRNA delivery platform from Spikevax, its development endpoints are oncology metrics such as RFS, DFS, or EFS, and it is used in combination with pembrolizumab. Approval, pricing, and reimbursement follow the oncology drug and BLA pathways rather than the ACIP or CDC vaccine channels. Demand is determined by the number of newly diagnosed cancer patients, while production costs also involve customized manufacturing for each individual patient. Its overall characteristics are therefore closer to individualized cancer therapy and CAR-T than to a mass-produced vaccine. This distinction also limits spillover effects for upstream vaccine suppliers. The report expects the INT patient population to number in the tens of thousands, while mass-market vaccines address tens of millions of people. During the 2024—2025 influenza season, 41.9% of US adults and 50.2% of children received at least one influenza vaccination, implying that annual influenza vaccine recipients alone substantially exceed 100 million people, even before including COVID-19, RSV, shingles, and pneumococcal vaccines. US vaccine prescription volume recorded by IQVIA declined by approximately 10% from 91.3 million in 2024 to 82.3 million in 2025, consisting of 46.8 million respiratory vaccine prescriptions, 34.9 million viral vaccine prescriptions, and 0.6 million bacterial vaccine prescriptions, below the pandemic-driven peak of 271.9 million in 2021. These figures represent prescriptions rather than unique vaccinated individuals and may omit some vaccination settings, but they are still sufficient to show that INT is only a small fraction of annual vaccine activity. Fifth, for Merck, commercialization rights and revenue opportunities do not equate to a large incremental profit contribution. Merck will be responsible for global commercialization, with Moderna co-promoting in the United States and Merck exclusively marketing and selling outside the United States. The report believes Merck's approximately US$50 billion increase in market capitalization cannot be attributed to Moderna-like platform optionality or a short squeeze and is also difficult to explain solely through INT fundamentals. Individualized manufacturing produces gross margins below Merck's average, and the two companies must share profits. Consequently, even under optimistic sales assumptions, INT could still weigh on Merck's operating margin. Moderna management expects the gross margin to improve over time, but it may not reach its long-term level during the initial launch period. In the report's data table, MRK had a closing price of US$152.20 and a target price of US$105.00, with relative performance of 59.6% in the table, and was also rated Market-Perform. Sixth, INT is not a comprehensive substitution threat to other oncology drug companies because most indications are designed as additions to existing standards of care. In early-stage treatment, as the Keytruda treatment base expands, Bristol-Myers Squibb's Opdivo faces some share risk in melanoma and non-small cell lung cancer, Roche's Tecentriq in non-small cell lung cancer, and AstraZeneca's Imfinzi in non-small cell lung cancer. Some bladder cancer regimens may also involve replacing existing treatments, but many programs remain purely incremental combinations. For first-line metastatic melanoma and non-small cell lung cancer, numerous studies are underway, and the report believes more data are needed before INT's competitiveness relative to other first-line regimens can be assessed. Whether the platform can replicate the melanoma results in immunologically “colder” tumors also remains unresolved. Finally, the report places the rally within a broader capital-rotation backdrop. Biopharmaceuticals reached new highs in 2026 as investors shifted from assets with concentrated technology and AI exposure toward pharmaceuticals. The report observes that pharmaceutical and semiconductor indices have been trading in opposite directions. Pharmaceuticals are viewed both as a relatively clear defensive option against AI concentration and as a sector that could be rerated as the market increasingly accepts it as a long-term beneficiary of AI. The report believes AI could erode the long-term growth of certain industries, while pharmaceuticals may use AI to enhance long-term value, meaning that the sector's rally is not attributable solely to the INT event. However, this positive industry-level thesis does not change Bernstein's stock-specific stance of maintaining Market-Perform ratings on MRNA, MRK, and BMY.

Analysis framework

The report first assesses the strength of the clinical signal using the statistical threshold for the first interim analysis of the Phase III trial and the existing Phase II results. It then calculates INT's addressable opportunity by indication, trial phase, and epidemiological population, using Keytruda's early-stage cancer revenue portfolio as a cross-reference. It subsequently decomposes the share-price reaction into fundamental validation, platform expectations, short covering, and news-headline effects, while analyzing commercial economics through patient volume, customized manufacturing, pricing, gross margin, and profit sharing. Finally, the report compares INT's overlap with existing oncology standards of care on an item-by-item basis and explains the biopharmaceutical rally in the context of concentrated AI exposure and sector rotation.

Methodology notes

• Event Strategies and Behavioral FinanceEvent-driven analysis

  Decomposition of the share-price reaction following the clinical readout

  Rather than attributing MRNA's approximately 170% event-driven gain entirely to clinical value, the report separately examines trial derisking, platform optionality, short covering involving approximately 15% of the float, and the headline effect of a “cancer vaccine.”

• Event Strategies and Behavioral FinanceExpectation Gap/Expectation Management

  Comparison between opportunity size and the increase in market capitalization

  The report compares the US$2.4 billion non-risk-adjusted sales model and the scope of the existing clinical programs with the substantial increases in MRNA's and MRK's market capitalizations to determine whether the market reaction exceeds the visible fundamental contribution.

• Industry/Sector Analysis FrameworkSupply-demand framework

  Market sizing based on epidemiology and clinical-program coverage

  The report defines demand by cancer type, treatment stage, number of trials, and addressable patient population, noting that INT-001 represents approximately 30% of the epidemiologically addressable opportunity in the pivotal programs and that demand comes from newly diagnosed patients rather than mass vaccination rates.

• Industry/Sector Analysis FrameworkVolume-price decomposition

  Joint analysis of patient volume, drug pricing, and profit margins

  The report compares INT's tens of thousands of patients with the tens or hundreds of millions of vaccine doses while also considering INT's expected premium pricing over Keytruda, individualized production costs, and the effect of profit sharing on final earnings.

• Competition and Strategy FrameworkValue chain analysis

  Individualized manufacturing and commercialization value chain

  The report follows the chain from tumor sequencing and algorithmic neoantigen selection to single-patient mRNA production, US co-promotion, and exclusive overseas sales to analyze the value that Moderna, Merck, and upstream vaccine-input suppliers can each capture.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Moderna (MRNA)

  INT-001 provides the first pivotal-trial validation of its mRNA platform for oncology applications beyond respiratory vaccines.

  Strengths

  Mature and consistent Phase II results have reduced risk, positive results at the first Phase III interim analysis further validate the platform, and the company has a pipeline spanning multiple early-stage and metastatic cancers.

  Weaknesses

  Individualized production has limited scale, gross margins may be low during the initial launch period, and the current share-price reaction exceeds the fundamental value that can be explained by the existing INT programs.

  Comparison

  INT uses a CAR-T-like, single-patient customized process but does not require chemotherapy-based lymphodepletion. It is expected to be priced above Keytruda and used in combination with Keytruda rather than as a mass-market prophylactic vaccine.

  Risks

  Efficacy in immunologically colder tumors has not yet been validated, and metastatic indications also require more competitive data.

• Merck (MRK)

  Responsible for INT's global commercialization and holds exclusive marketing and sales rights outside the United States; INT regimens are built on a Keytruda treatment backbone.

  Strengths

  Keytruda already has a substantial early-stage cancer market and commercial foundation, and INT can expand its combination-treatment portfolio.

  Weaknesses

  INT's gross margin may be below Merck's average, while profit sharing with Moderna will weigh on operating margin.

  Comparison

  Revenue from Keytruda's early-stage indications was approximately US$7.920 billion in 2025 and is projected to reach US$9.173 billion in 2028, while INT overlaps with only part of its indication portfolio.

  Risks

  The report believes the approximately US$50 billion increase in market capitalization is difficult to support solely through INT's currently visible profit opportunity.

• Bristol-Myers Squibb (BMY)

  Its Opdivo may face share pressure from the Keytruda-plus-INT combination in portions of the early-stage melanoma and non-small cell lung cancer markets.

  Strengths

  Opdivo is one of the existing standards of care in the relevant adjuvant-treatment settings.

  Weaknesses

  Expansion of the Keytruda treatment base through INT combinations may weaken Opdivo's market position.

  Comparison

  The report notes that Opdualag failed to demonstrate a benefit over Opdivo monotherapy, while INT plus Keytruda has achieved positive results in the relevant melanoma setting.

  Risks

  There is some substitution risk in the early-stage melanoma and non-small cell lung cancer markets.

• Roche (ROG)

  Tecentriq may be affected in portions of the early-stage non-small cell lung cancer market by the expansion of the Keytruda-plus-INT combination.

  Strengths

  Tecentriq already participates in the relevant non-small cell lung cancer treatment market.

  Weaknesses

  The INT programs may expand the Keytruda treatment base and create share pressure.

  Comparison

  INT-002 and INT-009 overlap with some of Keytruda's early-stage lung cancer indications.

  Risks

  If the relevant studies succeed, there is a risk that existing standards of care will be partially displaced.

• AstraZeneca (AZN)

  Imfinzi may face competition from the Keytruda-plus-INT combination in portions of the early-stage non-small cell lung cancer market.

  Strengths

  Imfinzi is an existing competing regimen in the relevant lung cancer treatment settings.

  Weaknesses

  Expansion of the Keytruda treatment base may weaken its market share.

  Comparison

  The report lists Imfinzi alongside Opdivo and Tecentriq as regimens that could be affected by early-stage INT combinations.

  Risks

  Successful early-stage lung cancer studies of INT could create some market-share risk.

Key data

• INT-001 Primary EndpointsRFS and DMFS were both positive at the first interim analysisSpecific hazard ratios and statistical data have not yet been disclosed
• Report-Estimated Hazard RatiosRFS approximately 0.65 to 0.50; DMFS potentially close to 0.40Estimated from the interim-analysis efficacy threshold and Phase II reference; not formally disclosed by the company
• INT Clinical Programs4 Phase III and 5 Phase II studiesPhase III includes melanoma and 3 NSCLC studies; Phase II covers renal cell carcinoma, two types of bladder cancer, and two first-line metastatic studies
• INT-001 Share of OpportunityApproximately 30%; 17%Respective shares of the epidemiologically addressable opportunity in the current pivotal programs and all Phase II/III INT studies
• INT Sales Opportunity ModelUS$2.4 billionNon-risk-adjusted model for early-stage melanoma and lung cancer
• Keytruda Early-Stage Cancer RevenueUS$7.920 billion in 2025; US$9.173 billion in 2028EApproximately 25% of Keytruda's total revenue, used as a reference for INT's potential expansion opportunity
• MRNA Event-Driven RallyApproximately +170%The report believes the existing INT programs are insufficient to explain this gain on their own
• MRNA Short PositionApproximately 15% of the floatShort covering is considered an important factor amplifying the rally
• Increase in Merck's Market CapitalizationApproximately US$50 billionThe report believes lower gross margins and profit sharing make it difficult for INT economics alone to support this reaction
• Number of Individualized NeoantigensUp to 34 per patientSelected algorithmically based on the patient's tumor-sequencing results
• US Influenza Vaccination RateAdults 41.9%; children 50.2%Received at least one dose during the 2024—2025 influenza season
• US Vaccine Prescription Volume82.3 million in 2025Down approximately 10% from 91.3 million in 2024, with a peak of 271.9 million in 2021
• Composition of US Vaccine Prescriptions in 2025Respiratory 46.8 million; viral 34.9 million; bacterial 0.6 millionIQVIA TRx measures prescriptions, not unique vaccinated individuals
• MRNA Rating and PriceMarket-Perform; current price US$174.38; target price US$45.00As of August 20, 2026, relative performance in the table was 528.3%
• MRK Rating and PriceMarket-Perform; current price US$152.20; target price US$105.00As of August 20, 2026, relative performance in the table was 59.6%
• BMY Rating and PriceMarket-Perform; current price US$65.47; target price US$61.00As of August 20, 2026, relative performance in the table was 15.4%

Impact & implications

For Moderna, the most important impact of INT-001 is that it expands the credible application scope of the mRNA platform from respiratory vaccines into oncology therapeutics and provides a foundation for validating programs in other cancer types and rare diseases. However, the current share price already reflects expectations far beyond the existing US$2.4 billion non-risk-adjusted model. For Merck, Keytruda's installed base and global commercialization rights support revenue expansion, but individualized manufacturing and profit sharing between the two companies mean the profit contribution will be lower than the revenue scale might imply. For other oncology drug companies, INT is generally an add-on to standard therapy rather than a comprehensive substitute, but an expansion of the Keytruda treatment base could pressure the shares of Opdivo, Tecentriq, and Imfinzi in certain early-stage cancer markets. For the traditional vaccine supply chain, INT shares some technical inputs with vaccines, but the patient volumes differ by several orders of magnitude, so mass-market vaccine demand should not be extrapolated from it in the short term. At the industry level, biopharmaceuticals offer both defensive characteristics against concentrated AI exposure and the potential to be rerated as long-term beneficiaries of AI.

Risks

• Whether INT can replicate its melanoma efficacy in immunologically “colder” tumors remains uncertain.
• Competition in first-line metastatic melanoma and non-small cell lung cancer studies is intense, and current data are insufficient to prove INT's competitiveness relative to other regimens.
• Individualized manufacturing results in gross margins below the average for conventional drugs, while profit sharing between Moderna and Merck will further reduce Merck's operating margin.
• MRNA's approximately 170% event-driven gain and Merck's approximately US$50 billion increase in market capitalization exceed the range that can be directly explained by the current scale of the INT programs.
• As INT expands the Keytruda treatment base, Opdivo, Tecentriq, and Imfinzi face share risk in certain early-stage cancer markets.

What to watch

• Monitor the complete INT-001 hazard ratios, statistical results, and timing of the data presentation. Potential conferences include ESMO or SITC, but the specific schedule has not yet been determined.
• Monitor the Phase I pancreatic cancer data expected to be released during 2026.
• Monitor the randomized Phase II renal cell carcinoma data from approximately 300 patients. The report believes a 2027 release is more likely and that favorable results could potentially support registration.
• Monitor whether rare-disease data later in 2026 further validate the applicability of the mRNA platform outside respiratory diseases.
• Monitor whether studies in first-line metastatic melanoma and non-small cell lung cancer can demonstrate INT's competitiveness relative to existing regimens.
• Monitor INT's final pricing, gross margin during the initial launch period, and the pace at which it improves as production scales.